Ustekinumab Improves Psoriasis without Altering T Cell Cytokine Production, Differentiation, and T Cell Receptor Repertoire Diversity

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Tsuda, Kenshiro ^a   Yamanaka, Keiichi ^a   Kondo, Makoto ^a   Matsubara, Kimiko ^a   Sasaki, Ryogen ^a   Tomimoto, Hidekazu ^a   Gabazza, Esteban C ^a   Mizutani, Hitoshi ^a  

^a MIE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; T LYMPHOCYTE RECEPTOR; USTEKINUMAB;

ARTICLE; CD4+ T LYMPHOCYTE; CELL MATURATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; PSORIASIS; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL;

ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; PSORIASIS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84871266885     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051819     Document Type: Article

References (30)

1. Chandran V, Raychaudhuri SP, (2010) Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun 34: J314-321.
2. Naldi L, Griffiths CE, (2005) Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152: 597-615.
3. Stern RS, Fitzgerald E, Ellis CN, Lowe N, Goldfarb MT, et al. (1995) The safety of etretinate as long-term therapy for psoriasis: results of the etretinate follow-up study. J Am Acad Dermatol 33: 44-52.
4. Thaci D, (2008) Long-term data in the treatment of psoriasis. Br J Dermatol 159Suppl 2: 18-24.
5. Nijsten T, Margolis DJ, Feldman SR, Rolstad T, Stern RS, (2005) Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol 52: 434-444.
6. Papp KA, Tyring S, Lahfa M, Prinz J, Griffiths CE, et al. (2005) A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152: 1304-1312.
7. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, et al. (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366: 1367-1374.
8. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, et al. (2008) Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol 58: 106-115.
9. Nestle FO, Kaplan DH, Barker J, (2009) Psoriasis. N Engl J Med 361: 496-509.
10. Trinchieri G, (2003) Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146.
11. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, et al. (2007) Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 8: 950-957.
12. Aggarwal R, Manadan AM, Poliyedath A, Sequeira W, Block JA, (2009) Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. J Rheumatol 36: 914-917.
13. Parham C, Chirica M, Timans J, Vaisberg E, Travis M, et al. (2002) A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol 168: 5699-5708.
14. Presky DH, Yang H, Minetti LJ, Chua AO, Nabavi N, et al. (1996) A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci U S A 93: 14002-14007.
15. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, et al. (2007) A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 356: 580-592.
16. Leonardi CL, Kimball AB, Papp KA, Yeilding N, Guzzo C, et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 371: 1665-1674.
17. Papp KA, Langley RG, Lebwohl M, Krueger GG, Szapary P, et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371: 1675-1684.
18. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, et al. (2010) Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362: 118-128.
19. Igarashi A, Kato T, Kato M, Song M, Nakagawa H, (2012) Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 39: 242-252.
20. Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, et al. (2012) Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokine-producing mature T cells. PLoS One 7: e31465.
21. Hata H, Yoshimoto T, Hayashi N, Hada T, Nakanishi K, (2004) IL-18 together with anti-CD3 antibody induces human Th1 cells to produce Th1- and Th2-cytokines and IL-8. Int Immunol 16: 1733-1739.
22. Manel N, Unutmaz D, Littman DR, (2008) The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol 9: 641-649.
23. Yamanaka K, Fuhlbrigge RC, Mizutani H, Kupper TS, (2010) Restoration of peripheral blood T cell repertoire complexity during remission in advanced cutaneous T cell lymphoma. Arch Dermatol Res 302: 453-459.
24. Alwawi EA, Krulig E, Gordon KB, (2009) Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther 22: 431-440.
25. Trinchieri G, Pflanz S, Kastelein RA, (2003) The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 19: 641-644.
26. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, et al. (2006) IL-23 promotes tumour incidence and growth. Nature 442: 461-465.
27. Lebwohl M, Leonardi C, Griffiths CE, Prinz JC, Szapary PO, et al. (2012) Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 66: 731-741.
28. Gordon KB, Papp KA, Langley RG, Ho V, Kimball AB, et al. (2012) Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 66: 742-751.
29. Kimball AB, Gordon KB, Fakharzadeh S, Yeilding N, Szapary PO, et al. (2012) Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 166: 861-872.
30. Yawalkar N, Ferenczi K, Jones DA, Yamanaka K, Suh KY, et al. (2003) Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 102: 4059-4066.